Life Science Star for Germany in Financial & Transactional Listings.LMG Life Sciences 2015

Christoph W.G. Engeler

  • Warburgstrasse 50
  • 20354 Hamburg
  • Germany

Christoph Engeler is a partner in the Hamburg office. Mr. Engeler practices in the firm’s Corporate Department, focusing on corporate and regulatory matters in the healthcare and life sciences industries. He has a wealth of experience advising domestic and international hospital and nursing home operators as well as financial investors in healthcare institutions on M&A transactions and restructurings. He further advises public authorities on privatizations of healthcare institutions and joint ventures. In the life sciences sector, Mr. Engeler advises German and foreign pharmaceuticals companies and manufacturers of medical devices on M&A transactions as well as German and EU regulatory matters, including clinical trials, manufacturing, marketing authorizations, distribution, promotion and marketing, interaction with healthcare professionals, vigilance, and reimbursement.

Mr. Engeler is consistently ranked for Health Care by Chambers Europe Germany: “Christoph Engeler has a growing reputation for life sciences work, focusing on regulatory issues relating to healthcare facilities. Sources highlight his ‘commitment to the sector’ and report that he is ‘very knowledgeable and client-oriented.’” (2015). Clients appreciate that he is “extremely responsive and able to turn things around quickly” and observe that Mr. Engeler “takes a practical approach to the matter at hand.” (Chambers Europe Germany 2016)

LMG Life Sciences 2014 recognizes: “Engeler often handles entire product life-cycles from development to market and was involved in an advisory capacity in one of the industries recent major deals (…).”

Mr. Engeler’s experience includes advising: 

  • Antin Infrastructure Partners on the acquisition of amedes Group
  • Astellas Pharma on the acquisition of Ganymed Pharmaceuticals and sale of its dermatology business to LEO Pharma
  • BC Partners on the sale of 72% stake in laboratory operator Synlab to Cinven
  • Boston Scientific on the acquisition of StarMedTec, a manufacturer of medical laser Systems
  • Integrated Device Technology, Inc. on the takeover of Zentrum Mikroelektronik Dresden AG (ZMDI)
  • Juno Therapeutics on its cross-border acquisition of Stage Cell Therapeutics GmbH
  • Novartis/Sandoz on its acquisition of a biosimilar pipeline product and the rights to manufacture and commercialize the product for the European Economic Area from Pfizer
  • Novo A/S on the strategic investment in Evotec AG, a CRO providing drug discovery services
  • District of Salzlandkreis (Saxony-Anhalt) on sale of four hospitals
  • Siemens in connection with the legal separation of its global healthcare division (diagnostic medical devices) − one of the largest in this industry − involving more than 200 countries
  • The Carlyle Group on the acquisition of Alloheim (nursing homes, 2013)
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.